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bleeding time, the prothrombin time, and the
euglobulin clot lysis time). These have some useful'
neis as screening tests, but they have little sensitivi$
and, obviously, low specificity. They often do provide
some information about the cause of a manifest bleed'
ing tendency. However, they are generally not in-
foimative in the case of a thrombotic tendency. Fortu'
oratories.
derivates.
PHYSIOLOGICAL BACKGROUND
Blood clotting is of necessity a fast, dynamic' and
strictly controlle? Process. It is a massive reactionin'
volvirig a large nrlmber of blood components' ,H'
cells aid proleins, that should be trig-gered gutlTl I
- - .1 - f f i - ion+hz Lrrr t  ^nl r r  urhpn needed. I t  iS aS impAf ' tanJ efficiei-rtly but only w en eded. s s po* '
tant that cloiting does not occur when 
.th:re 11ifi
cause, as it is for it to 
".*t 
*n"" a vessel is damaged' '
The guiding principle in the control of this hemostauG;
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lable 14.1.
)verview of Commercially Available Hemostasis Tests
;/obal tests
Prothrombin time : classical/chromogenic
aPTT: classical/chromogenic
Thrombin time; classical
)oagulation factors
Frinctional librinogen (thrombin-clottable)
Functional prothrombin assay (sum of carboxylated and noncarboxylated prothrombin): staphylocoagulase, Echis carinatus
poison rr ' rrrr rru lv v tlr \.ll hi^h mnlenrler weioht-
Measurements of lunctional concentration using deficient plasmas: ll, V, Vll, Vlll, lX, X, Xl, Xll, high olecular eight
kininogen
cnromogeiic activity assessment: vll, vlll, lX, X, prekallikrein, endotoxin
nniilenieterminati6ns-(-et-isn, l1y19ig' fiorinogen, ll, Vll, Vlll, lX, X, von Willebrand factor
Rist6cetin cofactor activity ol von Willebrand factor
Multimeric pattern of von Willebrand factor
Fibrin formation
Fibrin monomer test
Reptilase time
Kinetic determination of fibrinogen, using batroxobin
Factor Xltt (quatitative-ty ;;il;;;hlo"racetic acid, quantitatively using specific antibodies)
Fibrinopeptide A (ELISA)
lnhibitors
AntitnromOin lll : activity (chromogenically), antigen (Laurell)
Thrombin-antithrombin lli complexes, antigen (ELISA)
r)
tPTT)
len (ELISA)
Jonic acid, ristocetin, thrombin
iA)
Fibrinolysis
nogenically); PAI-1, PAt-2, PAI-3 antigen (ELISA)
Its
TDP (ELISA), specific for fibrinogen and flbrin ctegraoallon products
tially.
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a detailed description of the properties of each compo-
"""i 
t"ou*tely, without touchihg on {unctions of re-
il; J;t 
"6"tt' 
Consequently-,. o1l{,a brief over-
;;; ;i sd*,eral key componenti individually will.be
pt."ri"i U"foi" r,l'*ostisis as a whole will be dis-
cussed.---fhiomAin 
Thrombin, or factor IIa' is the product
of it 
" 
series of proteolytic activation reactions of the
coagulation systim. Tirrombin has many functions
and"forms an important link between the various com-
ponents of the hemostatic process' It is best known for
ir;^;irtyl;-.o"""tt fibrinogen molecules into fibrin
,r,orrorndrc that rapidly aisemble to form fibrin
ih;;"it. Thrombin Lbo' activates factor XIII' which
i-h;; h;t the ability to cross-link fibrin threads to form
;Ge;"*ort. t'tttomUin is also a very.potent plate-
let activator, espectally when collagen is present,as
well.Theconcentrationofthrombinnecessarytortnrs
;;;;;it rr".y low, it may be in th9 subnanomolar
i""n". Thrombin has severil interactions with intact
ililh"h;i."itt, -ott of which are antithrombotic'
fufoti i*pottant is probably the fact that thrombin is
able to form a complex wiih thrombomodulin',a Pro-
tein that is Present on the endothelial cell membrane'
tni, 
"unr"t 
a change of the specificity of the Proteo-
lvtic action of thronibin so that it loses its procoagulant
Jroperties and acquires the ability to achvate Protern
6;it.,il;;ttbty iogether with. the cofactol Prgtein !'
forms a potent intiEoagulant (Esmon 1989)' Report-
"afy, 
antS*Uin also has"a number of extrahemostatic
actions. It has, among other things' be-en described as
enhanceing wound f,ealing pl stimulating-.prolifera-
tion of fibroblasts and a nu"mb'er of other cells' Lastly'
inromUi" plays an important rgle in i.!.re reactions 
lead-
ine to its bwn formaf,on' By its ability to activate the^.^&.i.; 
P;"teins factor V and factor VIII' it accelerates
thrombin formation by several orders of magnitude(Eaton et al.1986).
*"ii^tiiiit. - 
slooa platelets are small anucleate cells
that have an importint role in hemostasis' They- are
activated by a number of substances' among which
ui" tft-t"Uin, collagen, and ADP' Activation induces
scoid to sPherical, accomPa-
H"#:5:l:: ,ffixTfi:""?'
il; lh; op"n citulicular system' wiich communi-
cates with the surrounding plasma' Among lh-e syU-
;;;"; released are ADP,-f6r activating-neighboring
olatel"ts, coagulation factor V, von Willebrand factor'td;;;;", pl"atelet factot 4, and vasoactive substances
Ut" t"."oto"in. Platelets are capable of adhering to pro-
Gi"t of the subendothelial matrix' like collagelt' t9
;J;"t plasma proteins like fibrin' von Willebrand
factor and fibronectin, an
herence is mediated bY ce
tecrin familY (Furie and l
faEe recePtor for fibrin, (
activated before functic
whether this holds true :
tegrin familY.
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prostanoids are derived is attractive' albeit not yet
iompletely Proven'
Reactions
The process of coagulation is based on the activa-
tio.-of 
'"-"rr*og"t by"another enzyme' similar to the
il;il#i-tty?-;t it"m trypsino f en bv enterokina se
t" lh;h"tiri-. The noi'vlobsolete cascade theory
ilil;J;;agulation exclusively through-this princi-
*r.i /rrro.Farl"-o 1964\- the backbone oI the coagula-
activation of Prothrombin
,Ii'l$r TP;yl:"#i:'"i[
ow, this backbone can be
depicted as follows:
V I I a ) X a ) I I a
Factor VIIa can, in addition to factor X, also activate
f""d; ii, which then is also able to activate factor X'
V I I a ) I X a ) X a ) I I a
This mechanism can produce a considerable ampli-
fi""ti; of factor X activation even though the extent
ofdirectactivationviafactorVllaisrelative$small(Xi
;;;'.-\sA;;).'ittit t"t 
"*e 
differs from the classical co-
u*tution scheme, *itft itt intrinsic-extrinsic dichot-
;il;: ih; .".oetliiiott that contact activation of coagu-
i#; il;ffiiy"pi"yt 
"t 
it"Portant role ir aitro' aswell
as the discovery ot the |osio loop' has led to the de-
mise of this hYPothesis'
In purified systems, factor-Xa is also capable of lcti-
"";H;i;-;or"itott'V'u"J 
vru (Eaton et it' tg86' pos-
i",''i"ri.^ lggii. ir'i' 
"ulity i:i'"*X,":?:m 
to plav a rore
.e factors VIIa, IXa, and Xa
It",*i:'"ffi1"il:::::il
otential (Fig. 1a'1) (Mann ef
,t. tggii.ihe properties bf the prothrombinase com-
plex have been investilated in much detail' When fac-
i.i xl-rt*ut""d to a piospholipid surface' the K- for
prttnro*Ur, .or,rr",,io" is several orders of magni-
't 
td" lo*", than when factor Xa is free in solution
iM";r;-h. tggz)' Thit *"uttt that' without a phos-)tf"t.il"ia surface,'factot Xa would need 40 times the
"#;ti-oi;;-"-"""t""tration of prothrombin to be
ilil;"itilJ, *n"i"ut in the presence of .negatively
;;;gJ Ph"tittotipiat it performs-optimallv' even 
at
the norm al ptur* 
"t'o^itl-tl'ttuti 
on of 
. 
pro thrombin' The
otu"""a" ofihe cofactor, factor Va' increases the turn-
il;;;b"; or ttt" 
""'yme 
about a thousandfold
ivf""" lq8z, Nesheim et'al' 1979)' This means that
:ilpiet.e;rotf,to-Uittase, the-complex of factor Xa
and factor Va on a phospholipid surface' is a very effi-
cient enzym"; or,i thai converts prothrombin into
;#;il';.i"a*ty that under-normal physiological
conditions, ttre reaition rate is limited ohly pV diffu-
ti." ti oi.thrombin to the phospholipid surface con-
;ffi;; itt"-p-ttttombinase complex' ln addition to
enhancing its turnovei number' irhospholipid-bound
v[[[
V
hr"cyt
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rlbeit low level, presence of activated dotting factors
n circulating blood. Thus, a little factor YIIa is already
:resent, and zymogen form of factor VlI, when com-
rlexed to tissub facior, can readily be activated by 
"it-
:ulatinq factor Xa'
The-other leg of the initiation of the hemostatic pro-
:ess is the ad'herence of platelets to 
-the revealed
;ubendothelium, with subsequent platelet shape
:hanqe and release of active substances like ADP and
olateiet activating factor (Sixma and Wester 1977)'
ih"r" 
"untu 
binding of other platelets to the first layer
cf adhered platelets and a primary aggtegate starts to
form. In addition to platelet cell surface receptors,
Willebrand factor are re-
rggregation. Aggregation,
iother, can be observed in
rombin or ADP to Platelet
aggregation- is reversible.
If, in such primary aggregate! traces of thrombin are
formed, secondary irreversible aggregation ensues'
This happens when the usual laboratory conditions
aoplv and most likely also in aitro.
'hisitioe 
Feeilback. The tissue factor/Vlla cornplex
is a rather efficient activator of factor X and X, but at
the time of initiation of coagulation these factors do
not yet have available the aitivated cofactors' There-
iore'prothrombin conversio-n is initially a very ineffi-
cient'and slow process, leading only-tg trace amounts
of thrombin. These concentratibns of thrombin are far
from high enough to convert massive amounts of fi-
brinoseil into fi6rin, but they do lead to small scale
u.tiuu"tior, of the cofactors, factors V and VIII, and of
blood platelets. This latter activation leads, among
other things, to exposure of a procoagulant phospho-
lipid surfice (Zwill and He-mker 1982)' (Without
thrombin activation the adherence and aggregation of
platelets is not sufficient for the exposure of negatively
inarged phospholipid surface). Formation of small
amoints bf .oioptei" prothrombinase and factor Xase
enzyme compleies edsues,, leading to an increase in
the rate of thrombin production, the catalytic effi-
cienry of these comPlete
more than five orders of n
of the enzymes alone. Fron
quence eihibits a typical
with a very rapid increase
uct formation (Hemker and Kessels 199L)' Concentra-
tions of thrombin reach several hundred nanomoles
per liter, more than enough for efficient fibrin forma-
hon. Thus, with thrombii being the most important
physiological activator of blood platelets, and platelets
being neiessary for thrombin formation of any igf.or-
tancd, reactions involving platelets and coagulation
are closely interrelated. The classical view of hemosta-
sis as a two-stage Process (i.e., first platelet reactions,
then coagulation), iherefore, represents much too sim-
plified a model.
lnhibitory Reactions. Several inhibitory- reaction
Pathways run through this scheme -as well (Esmon
ieSZ;. Lntithrombin I"II and several other serine prote-
ase inhibitors inhibit thrombin and factor Xa at a slow
hindered.
Control
thelium, which surrounds the site of iniury,- has a
number of mechanisms for inhibiting procoagulant re-
actions. Fourth, blood flow keeps hemostatic reactions
localized since it dilutes any aCtivated components of
the hemostatic system that-drift away from site of in-
lury.' 'fi*" 
Localization. The general idea of time local-
ization is that procoaguhnl reactions are fast but
short-lived and ihat an-ticoagulant reactions are slow
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but persistent. The character of hemostasis as an
emergency process is reflected in the rapid increase of
the reaction rates of the procoagulant reactions. This is
a consequence of both the fact that coagulation is a
multistep process, with the intermediate steps acting
as amplifiers, and of the various positive feedback
mechanisms.
It is of great importance that the hemostatic reac-
tions at the site of an injury are efficiently shut off. af-
ter a while but neither too soon nor too late. Thus,
inhibitory mechanisms should initially keep a slack
reign on the procoagulant reactions but must halt
them a little later on. The initial trigger of the coagula-
tion system, the tissue factorMla complex, is blocked
within minutes by tissue factor pathway inhibitor,
which starts being effective as soon as sufficient factor
Xa is present. This, however, does not stop the activa-
tion of factor X by the factor Xase complex or the for-
mation of thrombin by the prothrombinase complex.
Here, antithrombin III and a number of other serpins,
which all are present in a relatively high concentration
in plasma, come into play. They first bind their target
enzymes in a weak reversible manner. This initial
complex is then converted into a nearly irreversible
one. Since the rate of inhibition is determined by the
speed of the initial complex formation, it is slow, in
spite of the high concentration of the inhibitor. Conse-
quently, the inhibitory capacity of the serpins is ini-
tially overpowered by the burst of enzymes generated
early in the procoagulant reactions. The inhibition rate
of the serpins is also linearly dependent on the en-
zyme concentration, a property that eventually limits
the concentration of active enzyme as the inhibitory
rate starts balancing the formation rate of the enzyme
later in the procoagulant reaction. Another phenome-
non that conceivably favors, and later counteracts,
procoagulant reactions is impediment of blood flow
inside the forming fibrin and platelet dot. Initially, the
dilution of active clotting factors is diminished, which
has a procoagulant effect. Eventually, though, con-
sumption of the clotting factor zymogens, without
their replenishment, leads to a decreasing rate of acti-
vation.
Space and Time Localization. It is noteworthy that
some of the same mechanisms that cause spatial local-
ization also lead to temporal localization. The prime
example of this is the occurrence of dotting reactions
on negatively charged phospholipid surfaces. As men-
tioned above, this confines clotting factors to the site
of vessel damage. But it also accelerates those reac-
tions quite considerably by effectively increasing the
enzyme size to include a relatively large area of phos-
pholipid surface, thereby concomitant$ increasing the
collision rate. Another example is the absence of blood
flow inside a clot. This prevents washout of thrombin
and other activated clotting factors, and in this man-
ner produces space localization. As described above, it
also has a temporal effect since clotting factor zymo-
gens are being consumed inside this region of stasis.
BLEEDING TENDENCY
History and Physical Examination
In general, a solitary bleeding episode is not a man-
ifestation of a general bleeding tendency but of a local
pathology. Only if there are repeated hemorrhages, if
large hematomas are seen, or if no local cause can be
found, should a bleeding tendency be considered. In
the case of platelet or vessel wall defects, mucosal
hemorrhages are encountered chiefly (epistaxis, bleed-
ing of gingiva, bleeding of endometrium, hematuria,
hemoptysis, and bleeding from the gastrointestinal
tract). In the case of coagulation factor deficiencies,
large and deep hematomas in muscles or joints are
more common. Bleeding is also seen at minor surgery
(e.9., dental extraction). Through the medical history,
one should try to ascertain the presence and character-
istics of the bleeding tendency. Inquiries should be
made about earlier dental extractions and tonsillec-
tomy. To be sure, these are "minor" operations, but
they demand a lot of hemostasis and are therefore
good measures of the severity of the possible underly-
ing disorder. In addition to this, one should enquire
about blood loss from other surgical or invasive opera-
tions, like puncfures, injections, and so on, blood loss
after parturition, and blood loss from small wounds.
Transfusions can be an indication of the significance of
the bleeding. Disturbed wound healing (keloid scar
tissue) is seen in cases of factor XIII deficiency. The
possibility of artifacts or withheld traumas (self-muti-
lation, battered-child syndrome) should also be con-
sidered. If the hemorrhagic tendenry has been present
from childhood, a congenital defect should be contem-
plated, although the inverse does not hold. Unex-
plained bleeding in a rniddle-aged person can be
caused by mild hemophilia. By means of a focused
family history with a family tree, it can be determined
whether or not a hereditary defect is involved and
how the defect is inherited. A negative family history
does not preclude a congenital defect, however, be-
cause there is a relatively high frequency (30Vo) of
spontaneous mutations and because clinical symp-
toms may be lacking in cases of mild hemophilia or in
heterozygotes.
A number of drugs can impair hemostasis. The ob-
vious example is acetylsalicylic acid. It is often difficult
to elicit the taking of acetylsalicylic acid. It must be re-
alized that the number of preparations containing
acetylsalicylic acid is enormous and that its effect is ir-
reversible and detectable until 10 days after its inges-
tion. Other nonsteroidal antiinflammatory drugs, like
indomethacin and ibuprofen, cause a reversible dis-
turbance of platelet function. Apart from medication,
inquiries must also be made about intoxications (alco-
hol, mushrooms, narcotics, chemicals in relation to
profession or hobby), whether blood products were
administered in the past, and whether there is a possi-
bility of inadequate nutrition. In addition it is essential
to know whether a patient receives oral anticoagulants
or another kind of antithrombotic therapy.
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omas, such as are found in Kasabach-Merritt syn-
drome, thromborytopenia and other symptoms of in-
travascular coaguiation may be observed'
Exploratory Laboratory Investigations
tion.
The Actioateit Pattiat Thromboplastin Time' The
tration of a factor is more than adequate to produce an
undisturbed aPTT. In the presence of a circulating an-
ticoagulant, the aPTT re-mains prolonged, because
even"half the concentration of the inhibitor will retain
a noticeable influence on the clotting time' In general,
Bleeding may be the first symptom of diseases of
the liver and kidney, (hemato-)oncological diseases,
autoimmune diseases, disturbances in gastrointestinal
absorption, and various infections. Therefore, it is al-
ways indicated to perform a complete physical exami-
nation. Specific attention should be given to pete-
chiae, ecchymoses, and hematomas on skin and
mucous membranes. The 
,aspect (color, elevated or
not), number, size and lodation should be noted. In
the case of a clearly palpable purpura, vasculitis
should be considered. Petechiae and multiple small
hematomas are especially common with thrombocyto-
penia, thrombocytopathy, and vasculopathy. Apart
from spider nevi, one should also look for other stig-
mata of liver disease. Extensive hematomas and acute
hemarthrosis in the absence of significant trauma gen-
erally point to coagulation factor deficiencies. Ankylo-
sis, muscular atrophy, and other functional distur-
bances of the motor system can be caused by old
untreated muscle or joint hemorrhages and also sug-
gest coagulation factor deficiencies. Other areas that
deserve attention are the aspect of scars (factor XIII de-
ficiency) and any signs of hereditary connective tissue
diseases that themselves cause an elevated bleeding
tendency, like Marfan's syndrome or Ehlers-Danlos
syndrome. One should also note the presence of tel-
angiectasia, including in the conjunctivae, on and
under the tongue, on the lips, and on the palms of the
hands and the soles of the feet, as is seen in Rendu-
Osler disease. In general, a bleeding tendency does
exist with such vessel anomalies, but an underlying
hemostasis defect does not. With extensive hemangi-
omas, such as are found in Kasabach-Merritt syn-
drome, thrombocytopenia and other symptoms of in-
travascular coagulation may be observed.
Exploratory Laboratory Investigations
Indications for requesting exploratory hemostasis
tests include analysis of a bleeding tendencY, in-
tention of a blind biopsy (liver, spleen, kidney) or
an endoscopic retrograde cholangiopancreatography
(ERCP), suspicion of diffuse intravascular coagulation,
vitamin K deficiency, insufficienry of the kidneys or
the liver, paraproteinemia, and amyloidosis. Preoper-
ative hemostasis investigation for screening purPoses
in the case of a negative history does not make sense
(Rapaport 1983; Suchman and Griner L986). The initial
investigation consists of the following determinations:
hematocrit and other relevant parameters from rou-
tine hematological studies, platelet count, activated
partial thromboplastin time, prothrombin time,
thrombin time, and bleeding time.
Platelet Count. In general, platelets are counted in
EDTA anticoagulated whole blood, using an auto-
mated cell counter. A low platelet count reduces the
validity of the procedure, as do a highly elevated
number of leukocytes, turbid samples, the presence of
many fragmentocytes, the presence of fragments of
nuclei in erythrocytes, much enlarged platelets, or the
presence of microaggregates of platelets, e.g., caused
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by inadequate mixing during blood acquisition. Pseu-
dothrombocytopenia arises when EDTA causes agglu-
tination of thromborytes (Lombarts and Delieviet
1983). This is not concomitant with a bleeding ten-
dency. In such cases, the platelet count will be normal
if performed on citrate anticoagulated blood.
The platelet count can also be determined in a
counting chamber or estimated from a blood smear.
The blood smear provides further information about
the size and aspect of the platelets, about the presence
of aggregates, and about potential underlying hemato-
logical disorders. Special attention should be paid to
fragmentocytes (microangiopathic blood picture) since
they indicate the presence of fibrin in the bloodstream
and therefore the occurrence of intravascular coagula-
tion.
The Actiaated Partial Thromboplastin Time. The
activated partial thromboplastin time (aPTT) is a re-
calcification time of citrate anticoagulated plasma, af-
ter preincubation with a contact activator (e.g., kaolin,
silica, elaginic acid) and in the presence of phospho-
lipid. Reference values are very much dependent on
the particular reagents and should, therefore, always
be specified by the laboratory.
Prolongation of the aPTT is found in cases of ac-
quired or congenital deficiency of factors I, II, V ,lX, X,
XI, and XII, provided the deficienry is sufficiently se-
vere. The coagulation factor sensitivity is dependent
on the reagents used (D'Angelo et al. 7990; Naghibi ef
aI. 7988). Deficiencies of factors VII or XIII do not af-
fect the aPTT. The aPTT is prolonged by the Presence
of circulating anticoagulants and heparin. The effect of
low molecular weight heparins is less pronounced.
Heparin is the most common cause of a prolonged
aPTT. It is uncovered by performing a reptilase time
that in contrast to the thrombin time, is normal. In or-
der to distinguish between a coagulation factor defi-
ciency and a circulating anticoagulant, the sample is
mixed 1:1 with normal plasma. In a factor deficiency,
the aPTT will be normal because a half-normal concen-
tration of a factor is more than adequate to produce an
undisturbed aPTT. In the presence of a circulating an-
ticoagulant, the aPTT remains prolonged, because
even half the concentration of the inhibitor will retain
a noticeable influence on the clotting time. In general,
such anticoagulants are antibodies directed against
phospholipids or apoprotein H (lupus anticoagulant)
or against specific coagulation factors (mostly factor
VIII). Fibrin degradation products may also cause a
slight increase of the aPTT.
Prothrombin Time. The prothrombin time (PT) is
the recalcification in the presence of tissue thrombo-
plastin. Prolongation of the PT is observed within
congenital or acquired deficiencies of factors I, II, V,
VII, and X. The factor sensitivity, again, is dependent
on the reagent used (Naghibi et aI. 1988). Most re-
agents cause the PT to be prolonged when the concen-
trations of factorsl I, VII, or X are 3OVo or less. Only a
very low concentration of fibrinogen (less than 0.5 g/l)
leads to a prolongation. Apart from this, the test is
prolonged by high concentrations of fibrin degrada-
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tion products, by a high heparin concentration, and
by some circulating anticoagulanls. In general, the PT
is less sensitive io inhibiiors than the aPTT. The
renders the same PT.
Thrombin Time. The thrombin time is the clotting
time of citrated plasma after addition of a low concen-
tration of tfuombin. The outcome is dependent mainly
vessels of the skin and the vessels of the subcutaneous
tissue. It is determined chiefly by the number and
function of platelets and by the properties of the ves-
sel wall. In addition, von Willebrand's disease also
causes the bleeding time to be prolonged' Standard
values ate very muih dependent on the methodology
used (Bowie ind Owen-1980)' Th" much-used tech-
nique according to I'tty is described in the following
paragraph.
' 
Tli'e frinciple of the bleeding time determination is
the measurement of the time a standardized skin
wound bleeds. The pressure on the vascular bed is
controlled by a manometer cuff around the upper
arm, inflated to +O mm Hg. After disinfection, three
rtnuil rtub wounds are made on the volar surface of
the forearm with a vaccinostyle' The maximal depth of
the wound that can be made with the vaccinostyle is 2
mm. Wounds should be made with a swift motion,
and superficial veins must be avoided. Bleeding-starts
within^1S to 30 seconds. For each wound, when a
determination are, for men, up to 3 minutes and, for
women/ up to 4 minutes. However, the line between
normal and abnormal is not absolute. A long but still-
normal bleeding time by no means precludes a disor-
der.
Vasodilation (high room temperature, fever, drugs)
may prolong the bleeding time, and vasoconstriction
can mask iprolonged bleeding time. Often, in the
case of an auloimmune thrombocytopenia, the bleed-
ing time is shorter than expected on the basis of the
severity of the thrombocytopenia. The opposite is true
in the iase of a thrombocYtoPathY.
Platelet Function Disorders
Thrombocytopenia. The reference range {ot !!t:
platelet connt ii 130 to 350 x 10e/L (130 to 350 x 10i/
irrtr,'). The number of platelets necessary for adequate-
hemostasis is dependent on their quality. A count of
40 x 10eil (40 x 103/mm3) will generally be associated
with a virtually normal bleeding time if the platelets
are functioning normally. If there is an impairment in
platelet functi6n, a count of 40 x 10e may lead to a
iarqe prolongation in the bleeding time. A prolonged
ble"eding timi is always^ to be expelted with a platelet
count lels than 40 x 10e/L (40 x 10'/mm').
The bleeding tendency caused by thrgmlocytope-
nia shows itself in petechiae, mucosal bleeding, and
hematomas. Mostly, thrombocytopenia is an acquired
disorder. The causes of thrombocytopenia are listed in
Table 14.2.
Thrombocytopathy, Distutbed Platelet Eunction.
The combination of a Prok
normal platelet count, ot
number of platelets and thr
the bleeding time, is usu
rytopathy, although it maY a
t6Urind's disease. A thrombocytopathy can be either
congenital or acquired. A platelet function test is nec-
essJry fo. the 
- 
definite diagnosis of a thrombo-
cytopathy (Day and Rao 1986). The most widely used
platelet function test is the aggregi
method, the degree of light scatteri:
plasma is measured in a
plasma, by virtue of its tu
pass. Aggregation of Platt
ind theieJor6lets mor-e light through. In this way, the
Table 14.2.
Causes of ThrombocYtoPenia
Disturbance in the formation of platelets
Decreased number of megakaryocytes in the bone
marrow
Disturbance in the maturation of the megakaryocytes
Increased breakdown of Platelets
lmmunological: uto- or alloantibodies
Increased turnover
Damaged platelets
Loss of bldod platelets: massive bleeding, transfusion of
platelet-poor blood or substitution fluids, extracorporeal
circuits
Pooling of platelets: splenomegaly, hypersplenism
Pseudothrom bocytoPenia
ChAPtEr 14 / HEMOSTASIS AND THROMBOSIS 245
rytopathy, the platelet count and morphology are nor-
rial.'Phtblet function tests show no resPonse to ADP,
epinephrine, and thrombin but a normal resPonse to
;'stocitin. This disorder is inherited in an autosomal-
extracorporeal circulation, circulating 
- 
immune com-
plexes, ind vitamin Brz deficiency. Platelet function
hisorders are also found with congenital and acquired
cardiac valve defects.
deficiency, during recovery of a vitamin Brz or folic
acid deficiency, with hemolytic anemia, as a Parane-
oplastic phenomenon, and postoperatively.
'In 
esiential thrombocytosis both bleeding (espe-
cially in the digestive tract) and thrombosis may gclur'
Venbus thromLosis (mesentery veins, splenic vein), as
well as arterial thrombosis, occur, with ischemia of the
normalities of platelet function tests and do not cause
a bleeding tendency but, sometimes, they do induce
thrombosis.
Vascular Disorders
normal proteins.
Goagulation Factor Deficiencies
factor that are not functionally active'
Coazulation factors can be- assayed in two entirely
differeit ways, functionally or immunochemically' In
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functional determinations, the reaction velocity is
plasmin, and more (Table 1'4.1). Using purified fac-
iors, biochemical mixtures can be made in which the
tive and abnormal proteins. Therefore, molecular vari-
ants that are not functionally active will be detected by
the influence of stress or anemia, patients with mild
hemophilia A may show low-normal values of factor
VIII, ;hich may cieate rather difficult diagnostic prob-
lems.
The aPTT may be normal in mild hemophilia; in
moderate or serious hemophilia it is generally pro-
longed. The diagnosis is confirmed using a specific co-
agulation factor measurement.
" Antibodies may arise as a complication of the sub-
stitution therapy of hemophilia- For the determination
of the antibody titer a standardized method has been
developed (Beihesda test). Subject to the level of the
titer, pitients are designated as low or high respond-
ers.
are therefore difficult to identify as a carrier. [t is pos-
sible to use clinical data to cilculate the chances of
someone being a carrier, but it is much more reliable
to determine 
-carriership 
by way of DNA analysis
(White and Shoemaker L989; Thompson L986)'
oott Willebrand's disease. Patients with von Wil-
lebrand's disease have a congenital shortage or an ab-
normal kind of von Willebrand factor. von Willebrand
factor is a large plasma protein, circulating as a mul-
timeric protei-n iomplex^ consisting of 2 to 20 mole-
cules. von Willebrand factor has two functions' [n the
first place, it is necessary for the adhesion of platelets
to th! subendothelium. A disturbance of this function
shows in t:itro as a prolonged bleeding time, and in
the degree of factor VIII deficiency.
On lne basis of the inheritance pattern and the lab-
timeric pattern can be evaluated 
-by electrophoretic
techniques. By reason of mutual differences in this ab-
norrnuf multimeric pattern, several subtypes are dis-
cerned. The concentration of von Willebrand factor
and its functional activity are usually slightly de-
creased but often not to the same degree. Type IIB is
dency and a high mortality because of cerebral hemor-
rhage shortly "after birth. In other families clinical
svmptoms are very mild or lacking altogether' This
diff"r"tt." is probably caused by the fact that some-
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when factor XIII concentrations are below 5% ' False-
antibodies against individual coagulation factors or
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says presently commercially available (Bick 1988)'
Aiso, he* tecirniques based bn the use of monoclonal
antibodies have been developed that enable the deter-
tiate from DIC on the basis of laboratory tests' The
presence of a clear microangiopathic picture Javors
btC. Oth"t disorders from which DIC needs to be dif-
ferentiated are primary lysis of fibrinogen (in which
there is gene.ally a norrnal platelet count and an-
tithrombii III concentration), thrombotic thrombocy-
topenic purPura (in which there is usually a normal
fidrinogdn &ncentration and a normal antithrombin
III conientration, and little consumption of coagula-
the aPTT is less appropriate because the concentration
of factor VIII is often elevated. The average concentra-
concentration as well' If DIC is occurring, a prolonga-
tion of the thrombin time and a decrease of the fibrin-
ogen concentration will be seen' DIC may even be the
ci-use of the bleeding. Massive transfusion, on the
other hand, is able to provoke DIC to a certain extent'
mine sulphate.
Increased Breakdoutn of Fibrin. A bleeding ten-
in varieties of von Willebrand's disease, hemophilia,
or thrombocytopathy. Stress, vasoconstriction, and
other negative reactions may temporarily mask such
defects. Investigation of platelet function and determi-
nation of the factor VIII concentration (in rare cases,
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pletely normal despite the sometimes impressive
bleeding tendencY.
Finafy, it should be noted that a diminished-pro-
thrombin consumption is often the only abnormal lab-
oratory result found in mild bleeding tendencies that
are not further classifiable'
THROMBOTIC TENDENCY
Laboratory investigation of a thrombotic tendency
is indicated in patienls having unexplained thrombo-
sis at a young age (less than 45, years old) 9n{ a pogi-
tive family h-ist6ry. Only in about one third of the
cases will'an abnormality be found that explains the
thrornbotic tendency.
Antithrombin III deficienry is transmitted in an au-
tosomal dominant fashion. Absolute antithrombin III
deficiency (homozygous disease) does not occur,
probably'because iils incompatible with life' Partial
deficiencies (heterozygous disease) usually show a
concentration around 50%. The most frequent type,
type I, has both a lowered functional concentration
una u lowered antigen concentration. Structural vari-
ants of the antithrombin III molecule also exist (type
II) (Tollefson 1990). Some show a normal antigen con-
centration but a decreased functional concentration,
and others show a normal antithrombin III concentra-
tion but cannot be stimulated by heparin. When a de-
creased antithrombin III concentration has been ascer-
tained, it should be determined whether it is an
acquired deficienry resulting from decreased produc-
tion lliver disease, asparaginase therapy, estrogen
therapy), increased turnover- (serious bleeding, diffu se
intravascular coagulation, heparin therapy, 
.recent
thromboembolism), or loss via urine (nephrotic syn-
drome).
Congenital deficiency of protein C or S is usually
inheritdd in an autosomal dominant fashion' In the
Netherlands, the prevalence of protein C deficiency in
a nopulation of nonrelated families with thrombo-
pfrld in the Netherlands is about 5 to 10Vo ' In addi-
'tion 
to the dominant form, an autosomal recessive
protein C deficiency exists' Shortly after birth, homo-
zygotes develop the picture of a neonatal purpura
fui-minans. In ihese families, heterozygotes seldom
suffer from thrombosis. Therefore, not all individuals
with a protein C deficiency have an irtcreased risk of
thrombosis. Similar to antithrombin III deficiency, two
types of protein C deficiency are- distinguished:.type I
1io^w functional concentration, low concentration of
antigen) and type II (low functional concentration,
noriral'concenirition of antigen) (Miletich 1990)' As
vet, there is no consensus a6out the classification of
brotein S deficiency. This is, among other things, the
io.,t"qn"t 
"e 
of noi yet having eluiidated the role of
the C+l-binding protein, which- binds part of the pro-
tein S preseniin plasma. One useful classification is
the folbwing: pati^ents with a decreased totalprotein S
and a decreisdd ftee protein S antigen (not bound to
the C4-binding protein) and patients with a normal to-
tal but a low6rbd free protein S antigen. Functional
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protein S assays are being developed.(CgTp 1990).
For the interpretation of laboratory re-sults, it is impor-
tant to recognize that treatment with coumarin deri-
vates and vitamin K deficiency also lead to protein C
appeared to exist between a thrombotic tende-nry and
an- elevated concentration of histidine-rich glycopro-
bosis.
has not been established, however.
thrombotic tendencY.
LABORATORY CONTROL OF ANTITHROMBOTIC
AND THROMBOLYTIC THERAPY
The two most important kinds of thrombosis pre-
vention are oral antiioagulation with vitamin K antag-
onists and parenteral aiministration of heparin' Un-
fortunately,' there is no single laboratory test that
directlv reflects the antithrombotic action of the ther-
uou. Vfith both kinds of therapy, one has to make do
wiitr tests that correlate with th-e depth of the therapy
and with therapeutic ranges, established in clinical
practice, within which antithrombotic treatment is as-
iociated with an acceptably low risk of bleeding'
Oral Anticoagulation
The effect of oral anticoagulation is measured using
the PT or one of its variants (Hirsh 1991). It is sensitive
to changes in the concentrations of factors I, II, V, VII,
and X. With oral anticoazulation, the concentrations
of factors II, VII, IX, and X vary. In order to eliminate
the test's sensitivity to changes in the concentrations
of factors I and V, wnicn are not relevant in this case,
concentrations of factors II, VII, and X, as well as for
tion of a specific calculation have resulted in the so
called inteinational normalized ratio (INR). This is the
ratio of the PT of the sample to the PT of normal
ter administration of vitamin K, factor VII concentra-
tions are back to normal much sooner. If, e.g', a
plastin is satisfactory, provided that its therapeutic
ranqe comprlses a reasonable number of seconds, so
thaideviations of 1 or 2 seconds do not have an im-
Dortant influence on the outcome'
' 
Oral anticoagulant therapy, monitored using the
PT, calls for experience with the anticoagulant-drug,
as well as withihe method of control. In the Nether-
lands, monitoring is usually taken care of by the spe-
cialized thromboiis care centers' It should be clear
from what has been stated above, though, that truly
rational control of anticoagulation will not be possible
until research has show-n which changes brought
about by therapy are resPonsible for the therapeutic
effect and to what degree.
Heparin
therapeutic effect. The most important determinations
available are the aPTT, the thrombin time, the an-
tithrombin activity, and the antifactor Xa activity'
For the determination of the antithrombin and the
anti-Xa activitv, a fixed amount of thrombin or factor
Xa is added tb the patient's plasma sarnple, and the
amount remaining after a fixed incubation time is
measured. The ra[e of inactivation of these factors is
the bleeding tendency caused by heparin treatment'
However, tfie antifacior Xa activity hlrdly influences
thrombin formation and thus is very unlikely to con-
tribute to the effect of heparin in aitro.It is, though, a
helpful side effect of heparin therapy since it can be
meisured rather sensitively allowing, in particular,
the concentration of low molecular weight heparins to
be determined fairly well. It should be remembered,
however, that the relation between antifactor Xa activ-
ity and biological effect may be distinct for different
kinds of hepailn. The antithrombin activity is less sen-
sitive and is used less often, although it probably is
more relevant pathophysiologically. Both determina-
tions are in gen'eral cirried ou-t, using bovine coagula.-
tion factors ind in the absence of. Caz* , whereas in ai-
fro, human coagulation factors are inactivated in the
absence of Ca2*. The differences between these situa-
Chapter 14 / HEMOSTASIS AND THROMBOSIS 251
tions may have significant effects on the measurement
of different kinds of heParin.
The thrombin time ls insufficiently accurate and
sensitive to detect the low concentrations of heparin
present during prophylactic heparin therapy. It is, on
ihe other hand, a useful indicator in the titration
fect.
The most useful heparin determination is the aPTT,
provided that no extreme accuracy is required. The ef-
iect of heparin on the test is largely due to the inhibi-
tion of the thrombin-mediated activation of factor VIII'
In addition, the inhibition of factor IXa under the in-
fluence of heparin plays a role. The aPTT is less sensi-
tive to low mbleculir weight heparins but still remains
a useful tool.
receiving heparin therapy, the platelet count and fi-
brinogei concentration should also be determined in
order to preclude a heparin-induced thrombocytope-
nia or DIC.
Thrombolytic TheraPY
of these tests is minor.
tion products. Because of this, a very low concentra-
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tion of fibrinogen is often found in the fust hours after
the onset of treatment. An immunological assay that is
not disturbed by FDPs or a turbidimetric fibrinogen
determination renders more reliable data.
A potential problem in the evaluation of thrombo-
lytic therapy is that the proteolytic activity may con-
tinue in the specimen container, causing the test re-
sults not to be a reflection of the situation in uitro. This
can be precluded by having inhibitors of fibrinolysis
(tranexaminic acid, e-aminocaproic acid, aprotinin).
The predictive value of the laboratory results for the
risk of bleeding and/or reocdusion is low, which
means that, in practice, laboratory control is not very
useful. It is usually sufficient to demonstrate the lytic
state once by documenting a large reduction of the fi-
brinogen concentration and to monitor the aPTT, in
particular to establish a starting-point for subsequent
heparin therapy. The aPTT is generally not prolonged
very much.
EXERCISES
14.1. What laboratory studies should be ordered in
the evaluation of a patient who complains of the recent
onset of recurrent nose bleeds, bleeding gums, and scat-
tered petechiae?
't4.2. Not infrequently, patients with cancer experi-
ence disordered hemostasis. Describe some of the
mechanisms by which cancer and anticancer therapy can
result in disordered hemostasis.
14.3. A patient who has been receiving warfarin for 2
days has a PT of 18 seconds (control, 12 seconds; PT ra-
tio, 1.5). For the thromboplastin used, the INR (interna-
tional normalized Yl ratio) is 2.0. The patient has a calf
vein thrombosis for which the recommended INR inten-
sity is 2.0 to 3.0. Should this patient's warfarin dose be
changed?
REFERENCES
Bachmann F. 1990. Laboratory diagnosis of impairment of fibrinoly-
sis in patients with thromboembolic disease. Semin Thromb
Hemost 76:793-197.
Bick RL. 1988. Dsseminated intravascular coagulation and related
syndromes: a clinical review. Semin Thromb Hemost 74:299-338.
Bowie EJW and Owen CA. 1980. Standardization of the bleeding
time. Scand J Haematol [Suppl] 37:87-94.
Broze GJ, Girard TJ, and Novotny WF. 1990. Regulation of coagula-
tion by a multivalent Kunitz-type inhibitor. Biochemistry 29:7539-
7s46.
Como PC. 1990. Laboratorv evaluation of protein S status. Semin
Thiomb Hemost 16:7n-i81,.
D'Angelo A, Seveso MP, D'Angelo SV, Gilardini F, Dettori AG, and
Bonini P. 1990. Effect of clot-detection methods and reagents on
the activated thromboplastin time (APTT). Implications in heparin
monitoring by APTT. Am J Clin Pathol 94:297-306.
Day HJ and Rao AK. 1986. Evaluation of platelet function. Semin
Hematol 23:89-101,
Doolittle RF. 1984. Fibrinogen and fibrin. Ann Rev Biochem 53:195-
229.
Eaton D, Rodriguez H, and Vehar GA. 1986. Correlation of specific
cleavages by thrombin, factor Xa, and activated protein C with
activation and inactivation of factor VIII coagulant activity. Bio-
chemistry 25:505-512.
Esmon CT. 1987. The regulation of natural anticoagulant pathways.
Science 235 :I'348-7352.
Esmon CT. 1989. The roles of protein C and thrombomodulin in the
regulation of blood coagulation. J Biol Chem 264:47434746.
Foster \4I8, Nesheim ME, and Mann KG. 1983. The factor Xa-cata-
lyzed activation of factor V. J Biol Chem 258:1397U89n.
Furie B and Furie BC. 1988. The molecular basis of blood coagula-
tion. Cell 53:504-518.
George JN, Nurden AT, and Phillips DR. 1984. Molecular defects in
interactions of platelets with the vessel wall. N Engl J Med 2L1:
10811-1098.
Giesen PL, Willems GM, Hemker HC, and Hermens WT. 1991.
Membrane-mediated assembly of the prothrombinase complex. J
Biol Chem 266 :1,87 20-187 25.
Hemker HC and Beguin S. 1992. The mode of action of heparins in
oitro and in oiw. Adv Exp Med BioI 313:221-230.
Hemker HC and Kessels H. 191. Feedback mechanisms in coagula-
tion. Haemostasis 21:189-196.
Hemker HC, Veltkamp |f, Hensen A, et al. 1953. Kinetic aspects of
the interaction of blood clotting enzymes. IIl. Demonstration of
an inhibitor of prothrombin conversion in vitamin K deficiency.
Thromb Diath Haemorrh 19 :346-363.
Hirsh J. 1991. Oral anticoagulant drugs. N Engl I Med 324:1865-
r875.
Kane WH and Davie EW. 1988. Blood coagualtion factors V and
MII: structural and functional similarities and their relationship to
hemorrhagic and thrombotic disorders. Blood 71.:539-555.
Lombarts AfPF and Delieviet W. L988. Recognition and prevention
of pseudothrombocytopenia and concomitant pseudoleuko-
cytosis. Am J Clin Pathol 89:63LGi9.
Macfarlane RG. 1964. An enzyme cascade in the blood clotting
mechanism and its function as a biochemical amolifier. Nature
202:498499.
Mann KG. 1987. The assembly of blood clotting complexes on mem-
branes. Trends Biochem Ss 12:229-233.
Mann KG, Krishnaswamy S, and Lawson IH. I92. Surface-depend-
ent hemostasis. Semin Hematol 29:273-226.
Marder Vf and Sherry S. 1988. Thrombolytic therapy: current status.
N Engl J Med 318 (two parts):1512-'1.520, 1585-1594.
Miletich JP. 1990. Laboratory diagnosis of protein C deficienry.
Semin Thromb Hemost ]6:169-176.
Miiller-Berghaus G. 1989. Pathophysiology and biochemical events
in disseminated intravascular coagulation: dysfunction of
procoagulant and anticoagulant pathways. Semin Thromb
Hemost 15:5&S7.
Naghibi F, Han Y, Dodd WJ, and Lawrence CE. 1988. Effects of rea-
gent and instrument on prothrombin times, activated partial
thromboplastin times and patienUcontrol ratios. Thromb Haemost
59:455-463.
Nemerson Y. 1988. Tissue factor and hemostasis. Blood 71:1-8.
Nemerson Y and Furie B. 1980. Zymogens and cofactors of blood
coagulation. CRC Crit Rev Biochem 9:4S35.
Nesheim ME, Taswell JB, and Mann KG. 1979. The contribution of
bovine factor V and factor Va to the activity of prothrombinase. J
Biol Chem 254:1852-L0962.
Rapaport SI. 1983. Preoperative hemostatic evaluation: which tests,
if any? Blood 61,:229231.
Sixma JS and Wester l. L977. The hemostatic plug. Semin Hematol
14:265-299.
Suchman AL and Griner PF. 1986. Diagnostic uses of the activated
partial thromboplastin time and prothrombin time. Ann Intern
Med 1M:81G416.
Thompson AR. 1986. Structure, function, and molecular defects of
factor IX. Blood 67:56t572.
Tollefson DM. Laboratory diagnosis of antithrombin and heparin
cofactor II deficiency. Semin Thromb Hemost 76:162-168.
Travis J and Salvesen GS. 1983. Human plasma proteinase inhibi-
tors. Annu Rev Biochem 52:655-709.
Triplett DA. 190. Laboratory diagnosis of lupus anticoagulant.
Semin Thromb Hemost 16:1.82-192.
Tuddenham EGD. 1989. von Willebrand factor and its disorders: an
overview of recent molecular sfudies. Blood Rev 3:251-262.
Chapter 14 / HEMOSTASIS AND THROMBOSIS 253
whiteGcllandShoemakerCB'1989.FactorVIIgeneandhemo-
svnthetic PePtide subsbates in
,"ti. Clitt Biochem 29:35*i74'
l. 1989a. knPortance of factor-X-
rmation-the josso PathwaY-in
):301-308.
Xi M, Beeuin S, and Hemker HC' 1989b' The relative importance of^#;"&;tt 
ii, Vrr, IX and X for the prothrombinase activity in
il;";? 
".uUy 
o"ti"*g"Iated patients' Thromb Haemost 62:
788-791.
Zwall RFA and Hemker HC' 1982' Blood cell membranes and
haemostasis. F{aemostasis lll.12-39'
